Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Incyte Corporation
Merck Sharp & Dohme LLC
National Cancer Institute (NCI)
Hoffmann-La Roche
AstraZeneca
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Astellas Pharma Inc
Bristol-Myers Squibb
Radiation Therapy Oncology Group
National Cancer Institute (NCI)
National Cancer Institute (NCI)
AstraZeneca
Bristol-Myers Squibb
Hoffmann-La Roche
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
Bristol-Myers Squibb
Merck Sharp & Dohme LLC
Bristol-Myers Squibb
Daiichi Sankyo
Merck Sharp & Dohme LLC
Mural Oncology, Inc
AbbVie
National Cancer Institute (NCI)
American Regent, Inc.
SWOG Cancer Research Network
BeiGene
National Cancer Institute (NCI)
Eisai Inc.
National Cancer Institute (NCI)
Novartis
AbbVie
Celltrion
EMD Serono
Bristol-Myers Squibb
Samsung Bioepis Co., Ltd.
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Hoffmann-La Roche
AbbVie
BeiGene
Merck Sharp & Dohme LLC
Hoffmann-La Roche